Hyperprogressive disease after avelumab maintenance therapy in a patient with advanced ureter cancer: A case report
In the early stages of immunocheckpoint inhibitor administration, we should be aware of rapid cancer progression, known as hyperprogressive disease, in real-world clinical practice. We report a case of a 73-year-old man who presented with right abdominal pain and was diagnosed with advanced right ur...
Main Authors: | Keita Ogasawara, Daiki Ikarashi, Shinji Tamada, Takashi Tsuyukubo, Hiromitsu Fujisawa, Wataru Obara |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-11-01
|
Series: | Urology Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S221444202200290X |
Similar Items
-
Maintenance avelumab in a patient with metastatic urothelial carcinoma on hemodialysis: A case report
by: Sarah Belay, et al.
Published: (2022-12-01) -
A case of pseudoprogression in avelumab maintenance therapy for metastatic bladder cancer
by: Nozomi Hayakawa, et al.
Published: (2023-01-01) -
Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer
by: Yangchun Gu, et al.
Published: (2021-01-01) -
Maintenance immunotherapy in advanced urothelial cancer
by: María T. Bourlon, et al.
Published: (2022-07-01) -
IFN-γ and CD38 in Hyperprogressive Cancer Development
by: Stefania Angelicola, et al.
Published: (2021-01-01)